PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Clinical trials for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT explained in plain language.
Never miss a new study
Get alerted when new PROSTATIC NEOPLASMS, CASTRATION-RESISTANT trials appear
Sign up with your email to follow new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immune therapy joins fight against advanced prostate cancer
Disease control Recruiting nowThis study is testing whether adding an experimental immune therapy called pasritamig to standard chemotherapy (docetaxel) works better than chemotherapy alone for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The main goal is to see…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for tough prostate cancer: experimental drug trial opens
Disease control Recruiting nowThis study is testing an experimental drug called MK-5684, both alone and in combination with other treatments, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The main goals are to find a safe dose and see if the drug can…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
Radioactive 'Seek and Destroy' drug targets advanced prostate cancer
Disease control Recruiting nowThis study is testing a new two-step treatment for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. First, a radioactive scanning drug finds the cancer spots. Then, a related radioactive treatment drug is given to target and da…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1, PHASE2 • Sponsor: Clarity Pharmaceuticals Ltd • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC
-
New hope for Tough-to-Treat prostate cancer? scientists test novel drug duo
Disease control Recruiting nowThis study aims to find a safe dose for a new two-drug combination (TVB-2640 plus enzalutamide) for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. It will involve about 30 participants and is the first step in testing…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Mar 03, 2026 14:06 UTC